Malin Wickström

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. ncbi request reprint Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients
    Malin Wickström
    Department of Medical Sciences, Division of Clinical Pharmacology, Entrance 61, 4th Floor Uppsala University Hospital, SE 75185 Uppsala, Sweden
    Biochem Pharmacol 73:25-33. 2007
  2. ncbi request reprint The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo
    Malin Wickström
    Division of Clinical Pharmacology, Department of Medical Sciences, Entrance 61, 4th Floor Uppsala University Hospital, 75185 Uppsala, Sweden
    Mol Cancer Ther 6:2409-17. 2007
  3. ncbi request reprint The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro
    Malin Wickström
    Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University Hospital, Entrance 61, 4th Floor, 75185 Uppsala, Sweden
    Invest New Drugs 26:195-204. 2008
  4. doi request reprint The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan
    Malin Wickström
    Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University Hospital, S 75185 Uppsala, Sweden
    Biochem Pharmacol 79:1281-90. 2010
  5. doi request reprint In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues
    Caroline Haglund
    Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Cancer Chemother Pharmacol 69:697-707. 2012
  6. ncbi request reprint Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1
    Joachim Gullbo
    Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, SE 751 85 Uppsala, Sweden
    J Drug Target 11:355-63. 2003
  7. pmc Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
    Mårten Fryknäs
    Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University, Uppsala, Sweden
    BMC Cancer 13:374. 2013
  8. doi request reprint Aminopeptidase N (CD13) as a target for cancer chemotherapy
    Malin Wickström
    Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University Hospital, Uppsala, Sweden
    Cancer Sci 102:501-8. 2011
  9. doi request reprint Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia
    Elin Lindhagen
    Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    Eur J Haematol 81:344-53. 2008
  10. doi request reprint Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment
    Joachim Gullbo
    Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University Hospital, Sweden
    Biochem Pharmacol 82:139-47. 2011

Detail Information

Publications15

  1. ncbi request reprint Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients
    Malin Wickström
    Department of Medical Sciences, Division of Clinical Pharmacology, Entrance 61, 4th Floor Uppsala University Hospital, SE 75185 Uppsala, Sweden
    Biochem Pharmacol 73:25-33. 2007
    ..05), which may indicate some tumor selectivity. These results together with large clinical experience and relatively mild side effects encourage clinical studies of disulfiram as an anti-cancer agent...
  2. ncbi request reprint The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo
    Malin Wickström
    Division of Clinical Pharmacology, Department of Medical Sciences, Entrance 61, 4th Floor Uppsala University Hospital, 75185 Uppsala, Sweden
    Mol Cancer Ther 6:2409-17. 2007
    ..In conclusion, the melphalan prodrug J1 is highly active in models of neuroblastoma in vitro and in vivo, encouraging further clinical development in this patient group...
  3. ncbi request reprint The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro
    Malin Wickström
    Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University Hospital, Entrance 61, 4th Floor, 75185 Uppsala, Sweden
    Invest New Drugs 26:195-204. 2008
    ..In addition, the activity of J1 in combination with eight standard drugs, representing different mechanistic classes, was studied in nine different human tumor cell lines of different histopathological origin...
  4. doi request reprint The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan
    Malin Wickström
    Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University Hospital, S 75185 Uppsala, Sweden
    Biochem Pharmacol 79:1281-90. 2010
    ..Given that APN is shown to be overexpressed in several solid tumors our data suggest that J1 may be activated in a tumor selective manner...
  5. doi request reprint In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues
    Caroline Haglund
    Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Cancer Chemother Pharmacol 69:697-707. 2012
    ..The aim of this study was to evaluate a phenotypic cell panel with tumor cells from various patients and normal cells for preclinical profiles of antitumor efficacy and toxicity of anticancer drugs...
  6. ncbi request reprint Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1
    Joachim Gullbo
    Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, SE 751 85 Uppsala, Sweden
    J Drug Target 11:355-63. 2003
    ..Peptidase inhibitors inhibited the activity and intracellular release of melphalan, and dipeptide derivatives designed to resist the action of peptidases was less active than the corresponding normal dipeptide...
  7. pmc Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
    Mårten Fryknäs
    Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University, Uppsala, Sweden
    BMC Cancer 13:374. 2013
    ..Drug resistance is a common cause of treatment failure in cancer patients and encompasses a multitude of different mechanisms. The aim of the present study was to identify drugs effective on multidrug resistant cells...
  8. doi request reprint Aminopeptidase N (CD13) as a target for cancer chemotherapy
    Malin Wickström
    Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University Hospital, Uppsala, Sweden
    Cancer Sci 102:501-8. 2011
    ....
  9. doi request reprint Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia
    Elin Lindhagen
    Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    Eur J Haematol 81:344-53. 2008
    ..We have investigated the activity of gefitinib in haematological tumour cells, in particular acute myeloblastic leukaemia (AML)...
  10. doi request reprint Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment
    Joachim Gullbo
    Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University Hospital, Sweden
    Biochem Pharmacol 82:139-47. 2011
    ..The results indicate the feasibility of using PCPTC for cancer drug screening and that intracellular iron depletion could be a potentially important strategy for cancer therapy...
  11. ncbi request reprint Image-based screening for the identification of novel proteasome inhibitors
    Linda Rickardson
    Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University Hospital, 751 85 Uppsala, Sweden
    J Biomol Screen 12:203-10. 2007
    ..66. The results indicate that the assay rapidly identifies new proteasome-inhibiting substances, and it will be further used as a tool for image-based screening of other chemically diverse compound libraries...
  12. ncbi request reprint Simvastatin reduces the production of prothrombotic prostasomes in human prostate cancer cells
    Mikael Aberg
    Department of Medical Sciences, Clinical Chemistry, Akademiska Hospital, Uppsala, Sweden
    Thromb Haemost 100:655-62. 2008
    ..In conclusion, in prostate cancer, a nanomolar dose of simvastatin may have an anti-thrombotic effect due to decreased levels of circulating TF-bearing prostasomes...
  13. doi request reprint Alternative cytotoxic effects of the postulated IGF-IR inhibitor picropodophyllin in vitro
    Xuping Wu
    Section of Oncology, Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, Uppsala, Sweden
    Mol Cancer Ther 12:1526-36. 2013
    ..It is also suggested that PPT should be used as a reference compound in all future studies on PPP...
  14. ncbi request reprint The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro
    Dhana E Larsson
    Department of Endocrine Oncology, University Hospital, S 751 85 Uppsala, Sweden
    Anticancer Res 30:149-56. 2010
    ..The aim of this study was to investigate the apoptosis resulting from NSC 95397, brefeldin A, bortezomib and sanguinarine in neuroendocrine tumor cell lines...
  15. ncbi request reprint Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa
    Mikael Aberg
    Department of Medical Sciences, Clinical Chemistry and Pharmacology, Akademiska Hospital, S 751 85 Uppsala, Sweden
    Thromb Res 122:191-202. 2008
    ..We analyzed how simvastatin induces apoptosis in human breast cancer cells and the influence of FVIIa and/or FXa on the proposed apoptosis...